ZGNX News and Press, Zogenix Inc. From 04/08/19

The FDA has issued a Refusal to File (RTF) letter to Zogenix (NASDAQ: ZGNX ) related to its marketing application seeking approval for FINTEPLA (fenfluramine hydrochloride) for the treatment of seizures associated with a rare and severe form of epilepsy called Dravet syndrome. More news ...

EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug App...

EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First ...

EMERYVILLE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd., a leading Japanese pharmaceut...

HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits alleging the drug maker contributed to the deadly opioid crisis sweeping the U.S. This...

Zogenix, Inc. (ZGNX) Q4 2018 Results Conference Call February 28, 2019 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Stephen Farr - Chief Executive Officer Michael Smith - Chief Financial Officer Gail Farfel - Chief Development Officer Ashish Sagrolikar - ...

Zogenix (NASDAQ: ZGNX ): Q4 GAAP EPS of -$0.53 beats by $0.47 . Cash and equivalents of $514.2M. Shares +1.1% . Press Release More news on: Zogenix, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,

Completed rolling submission of an NDA to the U.S. FDA and an MAA to the EMA for FINTEPLA ® for the treatment of seizures associated with Dravet syndrome in February 2019 -- EMA has accepted MAA for review; outcome of the MAA review by the EMA expected in Q1 2020 -- Notic...

Zogenix (NASDAQ: ZGNX ) is scheduled to announce Q4 earnings results on Thursday, February 28th, after market close. More news on: Zogenix, Inc., Earnings news and commentary, , Healthcare stocks news, Read more ...

EMERYVILLE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018, after the market clo...